Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide

Journal of Leukocyte Biology

Volumn 72, Issue 5, 2002, Pages 939-945

  Mohty, Mohamad ^a   Stoppa, Anne Marie ^a   Blaise, Didier ^a   Isnardon, Daniel ^a   Gastaut, Jean Albert ^a   Olive, Daniel ^a,b   Gaugler, Béatrice ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b INSERM   (France)

Author keywords

Antigen presenting cells; Cancer; IL 12; Immune response; Immunotherapy

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; L CELL; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD; CELL DIFFERENTIATION; CELL LINE; CYTOKINES; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MONOCYTES; THALIDOMIDE;

ANIMALIA;

EID: 0036853590     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Anderson, K. C. (2001) Advances in disease biology: Therapeutic implications. Semin. Hematol. 38, 6-10.
2. Parman, T., Wiley, M. J., Wells, P. G. (1999) Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med. 5, 582-585.
3. Neubert, R., Nogueira, A. C., Neubert, D. (1992) Thalidomide and the immune system. 2. Changes in receptors on blood cells of a healthy volunteer. Life Sci. 51, 2107-2116.
4. Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., Kaplan, G. (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699-703.
5. D'Amato, R. J., Loughnan, M. S., Flynn, E., Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91, 4082-4085.
6. Haslett, P. A., Corral, L. G., Albert, M., Kaplan, G. (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. 187, 1885-1892.
7. Banchereau, J., Steinman, R. M. (1998) Dendritic cells and the control of immunity. Nature 392, 245-252.
8. Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., Kaplan, G. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177, 1675-1680.
9. Rowland, T. L., McHugh, S. M., Deighton, J., Dearman, R. J., Ewan, P. W., Kimber, I. (1998) Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 40, 11-20.
10. Moreira, A. L., Tsenova-Berkova, L., Wang, J., Laochumroonvorapong, P., Freeman, S., Freedman, V. H., Kaplan, G. (1997) Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tuber. Lung Dis. 78, 47-55.
11. Moller, D. R., Wysocka, M., Greenlee, B. M., Ma, X., Wahl, L., Flockhart, D. A., Trinchieri, G., Karp, C. L. (1997) Inhibition of IL-12 production by thalidomide. J. Immunol. 159, 5157-5161.
12. Haslett, P., Hempstead, M., Seidman, C., Diakun, J., Vasquez, D., Freedman, V. H., Kaplan, G. (1997) The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res. Hum. Retroviruses 13, 1047-1054.
13. Shannon, E. J., Sandoval, F. (1995) Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 31, 109-116.
14. Fernandez, L. P., Schlegel, P. G., Baker, J., Chen, Y., Chao, N. J. (1995) Does thalidomide affect IL-2 response and production? Exp. Hematol. 23, 978-985.
15. McHugh, S. M., Rifkin, I. R., Deighton, J., Wilson, A. B., Lachmann, P. J., Lockwood, C. M., Ewan, P. W. (1995) The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin. Exp. Immunol. 99, 160-167.
16. Jacobson, J. M., Greenspan, J. S., Spritzler, J., Ketter, N., Fahey, J. L., Jackson, J. B., Fox, L., Chernoff, M., Wu, A. W., MacPhail, L. A., Vasquez, G. J., Wohl, D. A. (1997) Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N. Engl. J. Med. 336, 1487-1493.
17. Peuckmann, V., Fisch, M., Bruera, E. (2000) Potential novel uses of thalidomide: Focus on palliative care. Drugs 60, 273-292.
18. Vogelsang, G. B., Farmer, E. R., Hess, A. D., Altamonte, V., Beschorner, W. E., Jabs, D. A., Corio, R. L., Levin, L. S., Colvin, O. M., Wingard, J. R., et al. (1992) Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. 326, 1055-1058.
19. Chao, N. J., Parker, P. M., Niland, J. C., Wong, R. M., Dagis, A., Long, G. D., Nademanee, A. P., Negrin, R. S., Snyder, D. S., Hu, W. W., Gould, K. A., Tierney, D. K., Zwingenberger, K., Forman, S. J., Blume, K. G. (1996) Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol. Blood Marrow Transplant. 2, 86-92.
20. Minchinton, A. I., Fryer, K. H., Wendt, K. R., Clow, K. A., Hayes, M. M. (1996) The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 7, 339-343.
21. Shimazawa, R., Miyachi, H., Takayama, H., Kuroda, K., Kato, F., Kato, M., Hashimoto, Y. (1999) Antiangiogenic activity, of tumor necrosis factoralpha production regulators derived from thalidomide. Biol. Pharm. Bull. 22, 224-226.
22. Gutman, M., Szold, A., Ravid, A., Lazauskas, T., Merimsky, O., Klausner, J. M. (1996) Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res. 16, 3673-3677.
23. Shurin, M. R., Lu, L., Kalinski, P., Stewart-Akers, A. M., Lotze, M. T. (1999) Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin. Immunopathol. 21, 339-359.
24. Macatonia, S. E., Hosken, N. A., Litton, M., Vieira, P., Hsieh, C. S., Culpepper, J. A., Wysocka, M., Trinchieri, G., Murphy, K. M., O'Garra, A. (1995) Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J. Immunol. 154, 5071-5079.
25. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., Gately, M. K. (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178, 1223-1230.
26. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J., Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565-1571.
27. Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y. T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S. P., Richardson, P. G., Schlossman, R. L., Morgan, G. J., Muller, G. W., Stirling, D. I., Anderson, K. C. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98, 210-216.
28. Lauwerys, B. R., Garot, N., Renauld, J. C., Houssiau, F. A. (2000) Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J. Immunol. 165, 1847-1853.
29. Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., Shaughnessy, J., Ayers, D., Spoon, D., Tricot, G. (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98, 492-494.
30. Dredge, K., Marriott, J. B., Todryk, S. M., Muller, G. W., Chen, R., Stirling, D. I., Dalgleish, A. G. (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol. 168, 4914-4919.